GSK and IDEAYA partner in synthetic lethality
admin 17th June 2020 Uncategorised 0The deal gives GSK access to IDEAYA’s MAT2A, Pol Theta, and Werner Helicase programmes
More: GSK and IDEAYA partner in synthetic lethality
Source: News
The deal gives GSK access to IDEAYA’s MAT2A, Pol Theta, and Werner Helicase programmes
More: GSK and IDEAYA partner in synthetic lethality
Source: News
Fierce Pharma Politics—Judge blocks Trump's 'most favored nation' drug pricing rule
Fierce Pharma Politics—Judge blocks Trump's 'most favored nation' d
Feds consider half-doses of Moderna COVID-19 vaccine to stretch supplies, as U.K. spaces out Pfizer, AstraZeneca shots
Feds consider half-doses of Moderna COVID-19 vaccine to stretch suppl
Pfizer, AbbVie, BMS, Teva, Sanofi, Gilead and others ring in 2021 with nearly 600 price hikes
Pfizer, AbbVie, BMS, Teva, Sanofi, Gilead and others ring in 2021 wit
© 1994 - 2021 B.M. Pharmaceuticals